Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet and vascular effects of aspirin in healthy persons and patients with type 2 diabetes
2016-000515-32Phase 4Completed
- Sponsor
- Per Løgstrup Poulsen
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aspirin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Per Løgstrup Poulsen. Primary endpoint: 24-hour antiplatelet effects of aspirin (maintenance therapy). Started Feb 2016; status: completed.
02
Drugs
aspirin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000515-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000515-32.